

Inflammatory Disease Pipeline

| | | | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 | Filed | Updates since Q3'20 |
|----------------------|---|------------------------------------|--------------|--------------------------------------|---------|---------|-------|-----------------------|
| Inflammatory Disease | Filgotinib JAK-1 inhibitor (GS-6034) | Ulcerative colitis | ▲ | MAA Filed | | | | MAA filed |
| | Filgotinib JAK-1 inhibitor (GS-6034) | Crohn's Disease | | | | | | |
| | Filgotinib JAK-1 inhibitor (GS-6034) | Psoriatic arthritis | ▲ | | | | | Removed from pipeline |
| | Filgotinib JAK-1 inhibitor (GS-6034) | Ankylosing spondylitis | ▲ | | | | | Removed from pipeline |
| | Filgotinib JAK-1 inhibitor (GS-6034) | Uveitis | ▲ | | | | | Removed from pipeline |
| | TPL2 inhibitor (GS-4875) | Ulcerative colitis | ▲ | | | | | Removed from pipeline |
| | TPL2 inhibitor (GS-5290) | Inflammatory Bowel Disease | ★ | | | | | New |
| | IRAK4 inhibitor (GS-5718) | Inflammatory Bowel Disease | | | | | | |
| | IRAK4 inhibitor (GS-5718) | Lupus | ★ | | | | | New |
| | Tirabrutintib BTK inhibitor (GS-4059) | CSU | ★ | | | | | New |
| | α4β7 inhibitor (GS-1427) | Inflammatory Bowel Disease | | | | | | |
| | Small molecule inhibitor (neutrophil target) | Inflammatory Diseases | | | | | | |
| | Small molecule inhibitor (innate immunity target) | Inflammatory Diseases | | | | | | |
| Fibrotic Disease | Cilofexor FXR agonist (GS-9674) | PSC | | | | | | |
| | Ziritaxestat ATX inhibitor (GLPG-1690) | IPF | | | | | | |
| | Cilofexor / firsocostat combination | NASH | | | | | | |
| | Selonsertib ASK1 inhibitor (GS-4997) | DKD | | | | | | |
| | Ziritaxestat ATX inhibitor (GLPG-1690) | Systemic Sclerosis | ▲ | | | | | Removed from pipeline |
| Options | Galapagos | Inflammatory and Fibrosis Diseases | | 8 clinical stage programs | | | | |
| | Galapagos | Inflammatory and Fibrosis Diseases | | Multiple pre-clinical stage programs | | | | |

★ New listing since Q3'20 ▲ Change since Q3'20

